Brief: Abionyx Pharma End-Dec Operating Loss Widens To 5.9 Million Euros

Abionyx Pharma SA

28/04/2022 17:21

April 28 (Reuters) - Abionyx Pharma SA  ABNX.PA :
    * CASH POSITION OF €7.9 MILLION AS OF DECEMBER 31, 2021
    * STRATEGIC PARTNERSHIP WITH IRIS PHARMA TO ACCELERATE
DEVELOPMENT
IN OPHTHALMOLOGY
    * ABIONYX PHARMA’S ACTIVITIES BEING DEDICATED TO THE
DISCOVERY AND
DEVELOPMENT OF INNOVATIVE THERAPIES TO IMPROVE THE LIVES OF
PATIENTS, GENERATED A REVENUE OF €27 K DURING THE FISCAL YEAR
2021
    * OPERATING INCOME FELL FROM A LOSS OF €2,968 K AT 31
DECEMBER
2020 TO A LOSS OF €5,952 K AT 31 DECEMBER 2021
    * NET INCOME THUS SHOWS A LOSS OF €5,822 K ON DECEMBER 31,
2021
COMPARED TO A LOSS OF €1,886 K ON DECEMBER 31, 2020
    * CASH AND CASH EQUIVALENTS AMOUNTED TO 7,935 K€ ON DECEMBER
31,
2021 AGAINST 9,154 K€ ON DECEMBER 31, 2020
    * THE BEGINNING OF 2022 REMAINS EQUALLY EVENTFUL AS IN
JANUARY
2022
    * ALL OF THE PRECLINICAL AND CLINICAL RESULTS FOR 2021 AND
THE
BEGINNING OF THIS YEAR POINT TO AN ACCELERATION OF THE
DEVELOPMENT OF CER-001 IN SEVERE RENAL DISEASES

Source text for Eikon:  urn:newsml:reuters.com:*:nBw4lwDtja
Further company coverage:  ABNX.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))